Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

SVP, CHIEF MEDICAL OFFICER

EVP, CHIEF FINANCIAL OFFICER

EVP, CHIEF SCIENTIFIC OFFICER

EVP, CBO AND CTO

EVP, CHIEF BUSINESS OFFICER

CHIEF FINANCIAL OFFICER

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis 10; autosomal dominant retinitis pigmentosa; and EDIT-301, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumor cancers; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-03-05	Premium	sold	Premium	Premium	Premium	CEO
2024-03-04	Premium	sold	Premium	Premium	Premium	SVP, CHIEF MEDICAL OFFICER
2024-03-02	Premium	acquired	Premium	Premium	Premium	EVP, CHIEF FINANCIAL OFFICER
2024-03-02	Premium	acquired	Premium	Premium	Premium	EVP, CHIEF SCIENTIFIC OFFICER
2024-03-02	Premium	acquired	Premium	Premium	Premium	CEO
2024-03-02	Premium	acquired	Premium	Premium	Premium	SVP, CHIEF MEDICAL OFFICER
2023-12-05	Premium	sold	Premium	Premium	Premium	EVP, CBO AND CTO
2023-11-14	Premium	sold	Premium	Premium	Premium	EVP, CBO AND CTO
2023-11-07	Premium	sold	Premium	Premium	Premium	EVP, CBO AND CTO
2023-09-06	Premium	sold	Premium	Premium	Premium	EVP, CBO AND CTO
2023-08-11	Premium	sold	Premium	Premium	Premium	EVP, CBO AND CTO
2023-08-08	Premium	sold	Premium	Premium	Premium	EVP, CBO AND CTO
2023-07-24	Premium	acquired	Premium	Premium	Premium	EVP, CHIEF SCIENTIFIC OFFICER
2023-07-19	Premium	sold	Premium	Premium	Premium	SVP, CHIEF MEDICAL OFFICER
2023-06-05	Premium	sold	Premium	Premium	Premium	CEO
2023-06-05	Premium	sold	Premium	Premium	Premium	EVP, CBO AND CTO
2023-05-17	Premium	acquired	Premium	Premium	Premium	EVP, CHIEF FINANCIAL OFFICER
2023-05-11	Premium	sold	Premium	Premium	Premium	EVP, CHIEF FINANCIAL OFFICER
2023-05-11	Premium	sold	Premium	Premium	Premium	EVP, CBO AND CTO
2023-05-09	Premium	sold	Premium	Premium	Premium	EVP, CBO AND CTO
2023-03-03	Premium	sold	Premium	Premium	Premium	EVP, CBO AND CTO
2023-03-03	Premium	sold	Premium	Premium	Premium	EVP, CHIEF FINANCIAL OFFICER
2023-03-02	Premium	acquired	Premium	Premium	Premium	SVP, CHIEF MEDICAL OFFICER
2023-03-02	Premium	acquired	Premium	Premium	Premium	EVP, CBO AND CTO
2023-03-02	Premium	acquired	Premium	Premium	Premium	EVP, CHIEF FINANCIAL OFFICER

EDIT - Editas Medicine Inc Stock Price, Fair Value and News

Latest Insider Trading transactions for EDIT